FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 665 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France February 20, 2024 EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide December 5, 2025 When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... May 21, 2019 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Ribociclib to Include Use in... Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... How My Metastatic Cancer Diagnosis Led Me to a Full-Time Career... FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a...
